Immunovia AB (publ)
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) (IMMVF) - Total Liabilities
Latest total liabilities as of December 2025: $23.42 Million USD
Based on the latest financial reports, Immunovia AB (publ) (IMMVF) has total liabilities worth $23.42 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immunovia AB (publ) - Total Liabilities Trend (2013–2025)
This chart illustrates how Immunovia AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Immunovia AB (publ) Competitors by Total Liabilities
The table below lists competitors of Immunovia AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FORCS Co.Ltd
KQ:189690
|
Korea | ₩5.51 Billion |
|
Wintergreen Acquisition Corp. Ordinary Shares
NASDAQ:WTG
|
USA | $66.27K |
|
WVS Financial Corp
OTCQX:WVFC
|
USA | $316.87 Million |
|
Baikowski SASU
PA:ALBKK
|
France | €25.80 Million |
|
Autech Corporation
KQ:067170
|
Korea | ₩482.93 Billion |
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
USA | $103.81 Million |
|
CItech Co Ltd
KO:004920
|
Korea | ₩38.91 Billion |
|
Aura Investments Ltd
TA:AURA
|
Israel | ILA4.21 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Immunovia AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunovia AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunovia AB (publ) (2013–2025)
The table below shows the annual total liabilities of Immunovia AB (publ) from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $23.42 Million | +9.47% |
| 2024-12-31 | $21.39 Million | -32.49% |
| 2023-12-31 | $31.69 Million | -44.19% |
| 2022-12-31 | $56.79 Million | -5.21% |
| 2021-12-31 | $59.91 Million | -3.03% |
| 2020-12-31 | $61.77 Million | +0.02% |
| 2019-12-31 | $61.76 Million | +300.27% |
| 2018-12-31 | $15.43 Million | +10.42% |
| 2017-12-31 | $13.97 Million | +106.15% |
| 2016-12-31 | $6.78 Million | -12.06% |
| 2015-12-31 | $7.71 Million | +146.21% |
| 2014-12-31 | $3.13 Million | +23.92% |
| 2013-12-31 | $2.53 Million | -- |